Overview

ten23 health was founded in 2021 and is a development, manufacturing and testing company for biotech start-ups and the established pharmaceutical industry.

Highlights

• Partnering with a highly experienced team of experts, including Prof. Dr Hanns Christian Mahler, with a proven track record in pharmaceutical product design and development
• As drug development activities across biologics modalities continue to accelerate, small biotechs and large pharma companies will increasingly outsource key services which require unique and market tested expertise
• ten23 health will deliver services in an engrained, fair and sustainable manner, respecting the future of the planet and people’s health
• Supported ten23’s acquisition of swissfillon, a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices, creating a vertically integrated CDMO with ten23’s Basel development lab and swissfillon’s scaled fill & finish manufacturing

Regulatory information 
This transaction involved a recommendation of 3i Investments plc.